title: Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease.
abstract: OBJECTIVE
  To evaluate the efficacy of one intravitreal injection of dexamethasone (Ozurdex(®); Allergan, Inc., Irvine, Calif., USA) in serous macular detachment (SMD) of one eye, associated with bilateral central retinal vein occlusion (CRVO) in a patient affected by Waldenström's macroglobulinemia (WM).
  
  
  METHODS
  A female patient, affected by WM, complained of a progressive decrease in visual acuity, mainly in the left eye (LE). SMD in the LE associated with bilateral CRVO was diagnosed. One intravitreal injection of dexamethasone was administered in the LE and the patient was tested 1, 2, and 6 months after the injection.
  
  
  RESULTS
  1, 2, and 6 months after the injection, the spectral domain optical coherence tomography (SD-OCT) showed a progressive slight reduction of foveal thickness that was not related to any improvement of visual function.
  
  
  CONCLUSIONS
  Treatment with dexamethasone (Ozurdex) induced a progressive slight reduction of SMD but no improvement of visual acuity, and it is possible that this is related to the condition of hematic hyperviscosity that is present in WM.
authors.affiliation: Ophthalmology Unit, NESMOS Department, S. Andrea Hospital, Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Rome, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Fenicia
authors.forename: Marco
authors.initials: M
authors.lastname: Balestrieri
authors.forename: Andrea
authors.initials: A
authors.lastname: Perdicchi
authors.forename: Giorgia
authors.initials: G
authors.lastname: Maraone
authors.forename: Santi Maria
authors.initials: SM
authors.lastname: Recupero
keywords: Dexamethasone; Intravitreal injection; Serous macular detachment; Waldenström's macroglobulinemia
references.citation: Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1157-60
references.pmid: 18326744
references.citation: Ophthalmology. 2011 Dec;118(12):2453-60
references.pmid: 21764136
references.citation: Retin Cases Brief Rep. 2013 Fall;7(4):319-24
references.pmid: 25383828
references.citation: Med J Malaysia. 2007 Oct;62(4):349-51
references.pmid: 18551947
references.citation: Arch Ophthalmol. 2006 Nov;124(11):1601-6
references.pmid: 17102008
references.citation: Adv Ther. 2011 May;28(5):351-66
references.pmid: 21494891
references.citation: Br J Haematol. 2002 Jul;118(1):344-7
references.pmid: 12100172
references.citation: Semin Oncol. 2003 Apr;30(2):110-5
references.pmid: 12720118
references.citation: Bull Soc Ophtalmol Fr. 1989 Jan;89(1):39-41
references.pmid: 2513133
references.citation: Eye (Lond). 2013 Jan;27(1):65-71
references.pmid: 23154502
references.citation: Clin Lymphoma Myeloma. 2009 Mar;9(1):100-3
references.pmid: 19362987
references.citation: J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):560-5
references.pmid: 23480270
references.citation: J Am Optom Assoc. 1989 Sep;60(9):657-8
references.pmid: 2507620
references.citation: Eye (Lond). 2008 Aug;22(8):1089-92
references.pmid: 18600248
references.citation: Ophthalmologica. 2013;229(1):21-5
references.pmid: 23006995